The FDA Roundtable Part II: REMS, Outcomes Studies and Drug Withdrawals
This article was originally published in RPM Report
Executive Summary
In Part II of The RPM Report’s roundtable discussion with three top FDA officials, the importance and implementation of FDA’s new REMS authorities, drug withdrawal precedents and the agency’s view of outcomes studies are the focus of the discussion.